Bookrunners Jefferies and Stifel Nicolaus help fund corporate purposes
By Toni Weeks
San Luis Obispo, Calif., Feb. 4 - Underwriters for NewLink Genetics Corp.'s public offering of stock fully exercised their over-allotment option, lifting total proceeds to $52.44 million. The offering priced on Jan. 30.
The company sold 4.6 million common shares at $11.40 per share, of which 600,000 shares comprised the greenshoe. The price per share is identical to the Jan. 29 closing share price.
Jefferies & Co., Inc. and Stifel Nicolaus Weisel were the joint bookrunners.
Proceeds will be used for general corporate purposes, including regulatory, clinical trial, research and development, general and administrative and manufacturing expenses.
The biopharmaceutical company is based in Ames, Iowa.
| Issuer: | NewLink Genetics Corp.
|
| Issue: | Common stock
|
| Amount: | $52.44 million (including $6.84 million greenshoe)
|
| Shares: | 4.6 million
|
| Price: | $11.40
|
| Warrants: | No
|
| Bookrunners: | Jefferies & Co., Inc., Stifel Nicolaus Weisel
|
| Co-managers: | Baird, Canaccord Genuity Inc. and Cantor Fitzgerald & Co.
|
| Announcement date: | Jan. 29
|
| Pricing date: | Jan. 30
|
| Settlement date: | Feb. 4
|
| Stock symbol: | Nasdaq: NLNK
|
| Stock price: | $11.40 at close Jan. 29
|
| Market capitalization: | $246.59 million
|
© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere.
For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.
